Our aim is to provide pharmaceutical and biotech clients with novel, differentiated products that have the potential to be highly marketable. We select our assets and design our development programs solely with this objective in mind.

We seek to commercialise our assets after establishing proof-of-mechanism and/or proof-of-principle in a clinical setting, thereby validating potential and discharging a significant proportion of the risk associated with early drug development.

We are always interested in talking to prospective commercial partners about our current programs and the ways in which we can help to provide access to the best drug-related intellectual property assets from the leading research institutions of the UK.